All In Biotech

Drug Trial Radar · NCT07603050

A Phase I/II Clinical Study to Evaluate the Safety and Efficacy of VGN-R08b in Patients With Type III Gaucher's Disease

A Phase I/II Clinical Study to Evaluate the Tolerance, Safety and Efficacy of VGN-R08b Intracerebroventricular Injection in Patients With Type III Gaucher's Disease

Last checked: Nov 20, 2026Latest source record: May 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

12

Planned (sponsor's estimate)

Start

May 14, 2026

Primary completion

May 29, 2028

Study completion Aug 16, 2032

Sponsor

Sponsor type
Industry
First posted
May 22, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 2 years, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A phase I/II clinical study to evaluate the tolerance, safety and efficacy of VGN-R08b intracerebroventricular injection in patients with type III Gaucher's disease

Conditions

  • Gaucher Disease Type 3

Interventions

  • VGN-R08bDrug

    6×10\^10 vg/g

  • VGN-R08bDrug

    1.2×10\^11 vg/g

  • VGN-R08bDrug

    1.8×10\^11 vg/g

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of adverse events (AE), Serious adverse events (SAE)Time frame: Up to 5 years

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.